Importantly, both antibodies confirmed that PTPRG is downregulated in the leukocytes of patients affected by CML, including CD34+CD38bright and CD34+CD38dim hematopoietic precursors. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.